Heparan sulfate isomers in cerebral arteries of Japanese women with aging and with atherosclerosis - Heparitinase and high-performance liquid chromatography determinations

Atherosclerosis

Volumn 132, Issue 1, 1997, Pages 9-17

  Murata, Katsumi ^a,b   Murata, A ^b   Yoshida, K ^c  

^a Osaka University of Arts   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c University of Tokyo   (Japan)

Author keywords

Atherosclerosis; Glycosaminoglycans; Heparan sulfates; Heparin; High performance liquid chromatography; Human cerebral artery

Indexed keywords

HEPARAN SULFATE;

AGING; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; BRAIN ARTERY; ELECTROPHORESIS; ENZYME SPECIFICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MEMBRANE PERMEABILITY; MOLECULAR INTERACTION; PRIORITY JOURNAL; SULFATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; CEREBRAL ARTERIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISACCHARIDES; ELECTROPHORESIS, CELLULOSE ACETATE; FEMALE; GLYCOSAMINOGLYCANS; HEPARITIN SULFATE; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; JAPAN; MIDDLE AGED; POLYSACCHARIDE-LYASES;

EID: 0030850849     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00049-X     Document Type: Article

References (37)

1. Nishimaru K, McHenry LC Jr, Toole JF. Cerebral and clinical differences in carotid system transient ischemic attacks between American Caucasian and Japanese patients. Stroke 1984;15:56.
2. Kotila M. Declining incidence and mortality of stroke, Stroke, 1984;15:255.
3. Whisnant JP. The decline of stroke. Stroke 1984;15:160.
4. Haheim LL, Holme I, Hjermann I, Leren P. Risk factors of stroke incidence and mortality. A 12-year follow-up of the Oslo study. Stroke 1993;24:1484.
5. Murata K, Hashimoto N. Acidic glycosaminoglycans, lipids and water in normal human cerebral arteries, Atherosclerosis 1984;51:307.
6. Murata K. Distribution of acidic glycosaminoglycans, lipids and water in normal human cerebral arteries at various ages. Stroke. 1986;16:687.
7. Murata K, Yokoyama Y. Acidic glycosaminoglycans in human atheroscelerotic cerebral arterial tissues. Atherosclerosis 1989;78:69.
8. Linker A, Hovingh P. In: McDuffie NM. (ed). Heparin: Structure, Cellular Functions and Clinical Applications, New York: Academic Press, 1979;3-24.
9. Hascall VC. In: Ginsburg V and Robbins P (eds). Biology of Carbohydrates, Vol. 1, Chichester: Wiley, 1987;1-49.
10. Wight TN, Lark MW, Kinsella MG. In: Wight TN and Mecham RP (eds). Biology of Proteoglycans. London: Academic Press, 1987;267-300.
11. Murata K, Yokoyama Y. Acidic glycosaminoglycan, lipid and water contents in human coronary arterial branches. Atherosclerosis 1982;45:53.
12. Murata K, Yokoyama Y, Yoshida K. Heparitinases facilitate separation of disaccharides of heparan sulfate isomers using high-performance liquid chromatography. Biochem Int 1989;19:55.
13. Murata K, Murata A, Yoshida K. High-performance liquid chromatographic identification of eight constitutional disaccharides from heparan sulfate isomers digested with heparitinase. J Chromatogr B 1995;670:3.
14. Murata K. Acidic glycosaminoglycan components in human atherosclerosis. In: Gotto AM and Crepaldi G (eds). Atherosclerosis Viii, Amsterdam: Elsevier, 1989;39-42.
15. Murata K, Yokoyama Y. Acidic glycosaminoglycans in human coronary arteries, with special reference to the presence of heparin or related glucosaminoglycan. Experientia 1981;37:1139.
16. Murata K. Enzymic determination of glycosaminoglycans. Application of chondroitinases and chondrosulfatases and high-performance liquid chromatography for identification of chondroitin and dermatan sulfate isomers. In: BeMiller JN (ed). Methods in Carbohydrate Chemistry, Vol. 10. New York: John Wiley and Sons, 1994;97-103.
17. Ototani N, Kikuchi M, Yoshizawa Z. Purification of heparinase and heparitinase by affinity chromatography on glycosaminoglycan-bound AH-Sepharose 4B. Carbohydr Res 1981;88:291
18. Bitter T, Muir HM. A modified uronic acid carbazole reaction. Anal Biochem 1962;4:330.
19. Murata K, Ogura T, Okuyama T. The acidic glycosaminoglycans in leukocytes - An application of enzymatic methods. Connect Tissue Res 1974;2:101.
20. Seno N, Anno K, Kondo K, Nagase S, Sato S. Improved method for electrophoretic separation and rapid quantitation of isomeric chondroitin sulfates on cellulose acetate strips. Anal Biochem 1970;37:197.
21. Wessler E. Analytical and preparative separation of acidic glycosaminoglycans by electrophoresis in barium acetate. Anal Biochem 1986;26:439.
22. Murata K, Sekino T, Ikeda T, Yoshida Y. Glycosaminoglycan components in duodenum with advancing age and in patients with progressive systemic sclerosis. Digestion 1995;56:230.
23. Murata K, Yokoyama Y. Enzymic analysis with chondrosulfatases of constituent disaccharides of sulfated chondroitin sulfate and dermatan sulfate isomers by high-performance liquid chromatography. Anal Biochem 1985;149:261.
24. Murata K, Yokoyama Y. Analysis of hyaluronic acid and chondroitin by high-performance liquid chromatography of the constituent disaccharide units. J Chromatogr 1986;374:37.
25. Murata K, Yokoyama Y. Liquid chromatographic assay for constituent disaccharides of hyaluronic acid and chondroitin sulphate isomers. J Chromatogr 1987;415:231.
26. Murata K, Nakazawa K, Hamai A. Distribution of acidic glycosoaminoglycans in the intima, media and adventitia of bovine aorta and their anti-coagulant properties. Atherosclerosis 1975;21:93.
27. Izuka K, Murata K. Inhibitory effects of human aortic and venous acidic glycosaminoglycans on thrombus formation. Atherosclerosis 1972;16:217.
28. Murata K, Yokoyama Y. High hyaluronic acid and low dermatan sulfate contents in human pulmonary arteries compared to the aorta. Blood Vessels 1988;25:1.
29. Murata K, Izuka K, Nakazawa K. Effects of acidic glycosaminoglycans in human aortic inner and outer layers on partial thromboplastin time. Atherosclerosis 1978;29:95.
30. Levesque H, Girard N, Maingonnat C, Delpech A, Chauzy C, Toyot J, Coutois H, Delpech B. Localization and solubilization of hyaluronan and of the hyaluronan-binding protein hyaluronectin in human normal and arteriosclerotic arterial walls, Atherosclerosis 1994;105:51.
31. Marcum JA, Atha DH, Fritze LMS, Nawroth P, Stern D, Rosenberg RD. Cloned bovine aortic endothelial cells synthesized anticoagulantly active heparan sulfate proteoglycan. J Biol Chem 1986;261:7507.
32. Vijayagopal P, Srinivasan S, Radhakrisshnamurthy, Berenson GS. Hemostatic properties and serum lipobinding of a heparan sulfate proteoglycan from bovine aorta. Biochim Biophys Acta 1983;758:70.
33. Kempen HJM, Buytenhek M, Gruber E, Bihari-Varga M. Factor, present in plasma, inhibiting the interaction of low density lipoprotein with arterial proteoglycan. Atherosclerosis 1989;78:137.
34. Imamura T, Mitsui Y. Heparan sulfate and heparin as a potentiator or a supressor of growth of normal and transformed vascular endothelial cells. Exp Cell Res 1987;172:92.
35. Labat-Robert J, Gruber E, Bihari-Yarga M. Interaction between fibronectin, proteoglycans and lipoproteins. Int J Biol Macromol 1990;12:50.
36. Wight TN. Cell biology of arterial proteoglycans. Atherosclerosis 1989;9:1.
37. Kruse R, Merten M, Yoshida K, Schmidt A, Yolker W, Buddecke E. Cholesterol-dependent changes of glycosaminoglycan pattern in aorta. Basic Res Cardiol 1996;91:344.